Skip to content
HowShorted

Puma Biotechnology Inc short interest in 2020

In 2020, Puma Biotechnology Inc's disclosed short interest ran from 20.08% of shares outstanding on 15 Jan 2020 to 16.79% on 31 Dec 2020, a change of -3.29 percentage points. The year's high was 21.94% on 31 Mar 2020 and its low 16.79% on 31 Dec 2020, averaging 19.19% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.96 days on 30 Oct 2020. Full history: Puma Biotechnology Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Puma Biotechnology Inc in 2020

2020 in figures

Start of year
20.08% (15 Jan 2020)
End of year
16.79% (31 Dec 2020)
Change
-3.29 pp
High
21.94% (31 Mar 2020)
Low
16.79% (31 Dec 2020)
Average
19.19%
Highest days to cover
18.96 (30 Oct 2020)
SEC filings marked
8

Every report in 2020

Puma Biotechnology Inc short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202020.08%5.57
31 Jan 202020.41%5.05
14 Feb 202018.84%1.79
28 Feb 202018.16%3.41results (8-K), 10-K filed
13 Mar 202018.75%6.05
31 Mar 202021.94%6.31
15 Apr 202021.66%8.59
30 Apr 202020.21%10.19
15 May 202020.02%5.6910-Q filed, results (8-K)
29 May 202018.91%9.54
15 Jun 202018.75%8.23
30 Jun 202017.32%5.70
15 Jul 202017.54%7.89
31 Jul 202017.81%12.27
14 Aug 202018.50%6.0710-Q filed, results (8-K)
31 Aug 202018.77%14.27
15 Sep 202018.60%12.60
30 Sep 202018.31%12.51
15 Oct 202019.73%15.43
30 Oct 202020.11%18.96
13 Nov 202020.32%14.6810-Q filed, results (8-K)
30 Nov 202019.48%16.25
15 Dec 202019.63%10.48
31 Dec 202016.79%13.35

See also: Puma Biotechnology Inc's full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.